Newscast – Page 88 – media

Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech

Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc., today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.
- Source: Kinetabio
- 517
- April 18, 2018
chronic pain Market Views nAChR
30% of Practices Look toward EHR Replacement Options by 2021

Black Book found that one-third of practices with more than 11 clinicians are considering EHR replacement options within the next few years.
- Source: EHR Intelligence
- 699
- April 18, 2018
digital health EHR Market Views
NHS Digital’s sharing of non-clinical patient data branded “inappropriate”

NHS Digital’s sharing of non-clinical patient information with the Home Office has been branded “entirely inappropriate” by MPs, who say they are concerned about the body’s ability to act as a reliable steward of the data.
- Source: DigitalHealth
- 698
- April 18, 2018
Company Insights digital health NHS
Supercharged sector as the Federal Government backs $200 million Digital Health CRC

In a major boost to Australia’s digital health sector, the Federal Government has announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre and its R&D consortium of more than 60 technology companies, universities, health networks and research institutes.
- Source: Healthcare IT
- 533
- April 18, 2018
digital health Market Views
Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
- Source: dndi
- 721
- April 17, 2018
Clinical Trials hepatitis C
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 992
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
- Source: finance.yahoo
- 704
- April 17, 2018
Company Insights oncology rare diseases
Telemedicine robot enables physician consultations in multiple locations

Using the device, called a Beam, Miramont Family Medicine now sees more patients than ever – enabling physicians to be in more than one of its four locations at the same time.
- Source: HealthIT News
- 580
- April 17, 2018
Company Insights mHealth Telemedicine
Sword Health lands $4.6M for digital physical therapy

Digital physiotherapy company Sword Health has brought in $4.6 million in a seed funding round led by Green Innovation, Vesalius Biocapital III, and other unnamed US and European investors.
- Source: MobiHealthNews
- 899
- April 17, 2018
AI Company Insights digital health
GSK hands rare disease gene therapies over to Orchard

Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies. The deal sees GSK become an investor in Orchard, with a 19.9 percent equity stake along with a seat on the firm’s board. The UK drugs giant also stands to receive royalties and commercial milestone payments related to the acquired portfolio.
- Source: pharmatimes
- 717
- April 16, 2018
GSK Market Views rare disease gene therapies

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.